INTRODUCTION

Acquired immunodeficiency syndrome (AIDS)-associated problems resulting from the HIV contributes to a significant number of mortalities every year. According to UNAID HIV and AIDS statistics (2020), globally, 37.7 million people have been infected and living with HIV, of which approximately 1.5 million were newly infected, and over 680,000 of them died from AIDS-associated ailments. The estimated prevalence of HIV in Pakistan is 0.1%, i.e., 183,705 people are living with HIV.

In developing countries, specifically Pakistan, the socioeconomic burden, including high poverty, illiteracy, unemployment, and increased healthcare cost, are likely to enhance the transmission of HIV. Although HIV is widespread...
in every population subgroup, it is spreading more rapidly among the male escorts as compared to female, demonstrating variety in local sexual practices. Furthermore, HIV is on the rise among intravenous drug users (IDUs), i.e., 38.4%. In many parts of Pakistan, IDUs involved in sexual activities with MSWs and transgender escalate HIV transmission, consequently following the Asian Epidemic Model.3,5,6

As per the HIV/AIDS prevention policies, early diagnosis and subsequent initiation of antiretroviral therapy (ART) remarkably reduces morbidity and mortality among patients infected with HIV. The timely provision of ART ensures appropriate management of opportunistic infections, preventing secondary transmission and associated complications, leading to improved health and prolonging the life expectancy among the people living with HIV.7,8 Although it is highly recommended to initiate the therapy before the infection begins, the delayed or interrupted HIV treatment initiations has been widely observed in developed and developing countries.9 The treatment onset and compliance vary with respect to culture and traditions worldwide.7

As of June 2020, 28.2 million people are receiving ART drugs, i.e., 73% of the total people living with HIV.1 While in Pakistan, only 10% of HIV patients are receiving ART with extremely low treatment compliance.3 However, with the increasing accessibility of HIV treatment, the rate of treatment discontinuation has also increased, resulting in a subsequent decline in the CD4+ T cell counts.10 Such patients are at higher risk of AIDS, morality and are a probable source of HIV transmission.11 Furthermore, ART efficacy tends to compromise with the development of HIV drug resistance (HIVDR).12 The low fidelity of HIV reverse transcriptase, rapid viral replication, and the selective pressure of antiretroviral drugs promote HIVDR.13

There has been a scarcity of data from Pakistan addressing the issue. Therefore, the current study aimed to assess the frequency of resistance to first-line antiretroviral therapy among HIV patients and its association with demographic characteristics.

METHODS

This cross-sectional study was conducted at the Department of Medicine, Lady Reading Hospital, Peshawar-Pakistan, from July 2020 to January 2021. A sample size of 162 was calculated using the WHO sample size calculator with a 6.5% margin of error, 95% confidence level, the prevalence of first-line antiretroviral resistance in HIV patients of 23.1%.14 Prior to inclusion, written informed consent was obtained from each patient or next of kin after explaining the study purpose. The study protocol was approved by the ethical review committee of Lady Reading Hospital (Reference no; 21/LRH Dated: 04/12/2018), and patient confidentiality was maintained.

All confirmed seropositive HIV patients between 18 to 70 years of age, both men and women receiving 1st line anti-retroviral therapy (ART), were included in the study, while non-consenting patients and HIV seropositive patients on 2nd line antiretroviral therapy were excluded. The patient’s detailed history, including age, gender, BMI, comorbid conditions, smoking status, viral load, and first-line antiretroviral response, were recorded using a structured questionnaire. Blood samples were drawn for phylogenetic profiling. The resistance to first-line antiretroviral therapy was determined on the basis of viral load.

Data were analyzed using SPSS version 22.0, frequency and percentages were used to present

| Variables       | N (%)       |
|-----------------|-------------|
| **Age; mean ± SD (Years)** | 45.44 ± 5.0 |
| **Gender**      |             |
| Male            | 77(47.5)    |
| Female          | 85(52.5)    |
| **Diabetes Mellitus** |         |
| Yes             | 64(39.5)    |
| No              | 98(60.5)    |
| **BMI (kg/m²)** |             |
| Overweight      | 51(31.5)    |
| Class-I Obesity | 38(23.5)    |
| Class-II Obesity| 16(9.9)    |
| **Hypertension**|             |
| Yes             | 88(54.3)    |
| No              | 74(45.7)    |
| **Smoking**     |             |
| Yes             | 80(49.4)    |
| No              | 82(50.6)    |
| **Resistant**   |             |
| Yes             | 57(35.2)    |
| No              | 105(64.8)   |

Table-I: Baseline characteristics of the patients.
categorical variables like gender, age groups, hypertension, diabetes mellitus, smoking status, and ART resistance. Mean and standard deviation was used for continuous variables like age and BMI. Post-stratification Chi-square test to see the effect modification by age, gender, body mass index, smoking, diabetes mellitus, and hypertension, where a p-value < 0.05 was considered statistically significant. Ethical Approval: (Ref: 2IILRH, Dated 04-12-2018).

RESULTS

Out of the total, 52.5% of HIV patients were females, and 47.5% were males. The mean age of these patients was 45.44 ± 5.0 years. The frequency of ART resistance was observed among 64.8% of the total HIV patients (Table-I). There was no significant effect of age, gender, smoking status, presence of diabetes, or hypertension on the HIV drug resistance. While only BMI was significantly associated with resistance status (p=0.023) (Table-II). Of the genotyped sample, the drug resistance mutations M184V and K103N were detected in the NRTIs, and NNRTIs, respectively, whereas the mutations G73SC and I47VA were detected in the PIs.

DISCUSSION

In the present study, we evaluated drug resistance and the phylogenetic profile of HIV patients presenting at the Lady Reading Hospital, Peshawar. To the best of our knowledge, this has been the first attempt from Peshawar, to address drug resistance among HIV patients referred through clinicians with suspected clinical or immunological failure.

The frequency of drug-resistant variants was 35.2% in the studied population, which is comparatively high than a study conducted in China reporting 19.5% patients with drug resistance variants. Similarly, an Italian study reported that around 21.8% of HIV patients were resistant to one drug class, 24.6% to two, and 12.9% to three drug classes. The high drug resistance reported in the present study could either be related to non-adherence to ART or late recognition of treatment failure.

The M184V mutation was more frequently observed than other mutations, determined as the major reason drug resistance to NRTIs. These findings were similar to other parallel studies. Furthermore, for NNRTIs, K103N was the most common mutated sequence, which is comparable to other studies, it is known to compromise

| Variables          | Resistant | p-value  |
|--------------------|-----------|----------|
|                    | Yes       | No       |          |
| Gender             | Male      | 32(56.1) | 45(42.9) | 0.106 |
|                    | Female    | 25(43.9) | 60(57.1) |       |
| Diabetes Mellitus  | Yes       | 22(38.6) | 42(40.0) | 0.861 |
|                    | No        | 35(61.4) | 63(60.0) |       |
|                    | Normal    | 15(26.3) | 42(40.0) |       |
| BMI                | Overweight| 17(29.8) | 34(32.4) | 0.023*|
|                    | Class-I Obesity | 21(36.8) | 17(16.2) |       |
|                    | Class-II Obesity | 4(7.0) | 12(11.4) |       |
| Hypertension       | Yes       | 34(59.6) | 54(51.4) | 0.316 |
|                    | No        | 23(40.4) | 51(48.6) |       |
| Smoking            | Yes       | 30(52.6) | 50(47.6) | 0.542 |
|                    | No        | 27(47.4) | 55(52.4) |       |

*p<0.05 is considered statistically significant.
efficacy of Nevirapine and Efavirenz. Additionally, the low genetic barrier of the NNRTI drugs permit resistance to these drugs. For protease inhibitors (PIs), G73SC and I47VA were common mutations observed. Unlike the other classes of ART drugs, the displayed resistance to PIs in the present study was contrast to other similar study. G73SC mutation considerably reduces the nelfinavir and saquinavir susceptibility, while high-level resistance to lopinavir and fosamprenavir and low/intermediate resistance to the remaining PIs except for atazanavir and saquinavir, has been contributed by I47VA mutation.

We found no significant factors influencing HIV drug resistance except BMI (p=0.023). Whereas Sebastiao et al. studied the factors influencing HIV drug resistance among pregnant females, they found a high frequency of drug resistance among the pregnant HIV females with other comorbidities, living in rural areas, and those with high educational status. Similarly, other studies also confirm that patients' age, residence, education, occupational status, comorbid conditions, and HIV-1 subtypes are the significant factors related to ART failure.

**Limitations of the Study:** Among the major limitations of the present study was its cross-sectional design and devoid generalizability; these outcomes cannot be generalized for the entire Pakistani population, as the study included only the HIV-positive patients from Peshawar attending the study site for treatment. The patient's residence and educational status weren't considered, which might have been significant influencers of drug resistance. Furthermore, the resistance testing was not performed prior to initiation of ART, and treatment adherence was not established; hence it is not imperative to say that all the resistance mutations occurred after ART initiation or because of non-adherence to ART.

**CONCLUSION**

There is a high frequency of ART-resistant variants among enrolled HIV patients, which highlights the importance of timely recognition of treatment failure. The mutations M184V and K103N were detected in the NRTIs and NNRTIs, respectively, whereas the mutations G73SC and I47VA were detected in the PIs. Furthermore, the provision and accessibility of genotypic testing remain a challenge; less expensive approaches for the assessment of viral load are highly essential in a country like Pakistan.

**Acknowledgement:** The authors are thankful to Medical Affairs department of Getz Pharma for their assistance in publication.

**Conflicts of Interest:** The author(s) declare no conflicts of interest.

**Funding:** None.

**Grant Support & Financial Disclosures:** The authors did not get financial support from any organization for the conduct of the study.

**REFERENCES**

1. UNAIDS. Global HIV & AIDS statistics — Fact sheet. Available at: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf
2. Global AIDS Monitoring 2020. Country progress report - Pakistan. Available at: https://www.unaids.org/sites/default/files/documents/PAK_2020_countryreport.pdf
3. Siddiqui MH, Siddiqui JA, Ahmed I. Demographic profile and clinical features of admitted HIV patients in a tertiary care teaching hospital of Karachi, Pakistan. Pak J Med Sci. 2009;25(5):861-864.
4. Altaf A. Is Pakistan at the cusp of an ART resistance. J Pak Med Assoc. 2020;70(11):2046-2047.
5. Ali Khan M, Faisal Khilji M, Janjua AR, Imran M, Altintas KH. Hepatitis B and C related knowledge, attitudes and practices of health care workers in Azad Kashmir, Pakistan - A potentially disastrous area. Int J Epidemiol. 2019;7(1):39-46.
6. Ali H, Zakar R, Junaid K, Khan A, Fischer F. Frequency and reasons for delayed treatment initiation after HIV diagnosis: cross-sectional study in Lahore, Pakistan. BMC Public Health. 2021;21(1):1-2.
7. Ingabire PM, Semitala F, Kamya MR, Nakanjako D. Delayed antiretroviral therapy (ART) initiation among hospitalized adults in a resource-limited setting: data from a cohort study in India. PeerJ. 2013;1:e90.
8. Ali Z, Waseem S, Anis RA, Anees M. Assessment of cell free mitochondrial DNA as a biomarker of disease severity in different viral infections. Pak J Med Sci. 2020;36(5): 860-866.
9. Alvarez-Uria G. Factors associated with delayed entry into HIV medical care after HIV diagnosis in a resource-limited setting: data from a cohort study in India. PeerJ. 2013;1:e90.
10. Ananworanich J, Gayet-Ageron A, Braz M, Prasithsirikul W, Chethothisakd P, Kiertiburanakul S, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet. 2006;368(9534):459-465.
11. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. Aids. 2002;16(7):1051-1058.
12. World Health Organization. Global Action Plan on HIV Drug Resistance 2017–2021. [Accessed on 15 September 2020]. Available at: https://www.who.int/hiv/pub/drugresistance/hivdr-action-plan-2017-2021/en/.

13. Pereira-Vaz J, Duque V, Trindade L, Saraiva-da-Cunha J, Melico-Silvestre A. Detection of the protease codon 35 amino acid insertion in sequences from treatment-naïve HIV-1 subtype C infected individuals in the Central Region of Portugal, J Clin Virol. 2009;46(2):169-172.

14. Kinyua JG, Lihana RW, Kiptoo M, Muasya T, Odera I, Muiruri P, et al. Antiretroviral resistance among HIV-1 patients on first-line therapy attending a comprehensive care clinic in Kenyatta National Hospital, Kenya: A retrospective analysis. Pan Afr Med J. 2018;29(1):1-6.

15. Li M, Liang S, Zhou C, Chen M, Liang S, Liu C, et al. HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China. Patho. 2021;10(3):264.

16. Lombardi F, Giacomelli A, Armenia D, Lai A, Dusina A, Bezenchek A, et al. Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database. Inter J AntimicrobAgent. 2021;57(2):106252.

17. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002;346(11):811-820.

18. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963-972.

19. Moscona R, Ram D, Wax M, Bucris E, Levy I, Mendelson E, et al. Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000-2014. J Int AIDS Soc. 2017;20(1):21846.

20. FDA News Release. FDA approves new HIV treatment. [Accessed: May 20, 2011]. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256087.htm.

21. Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, Non-Inferiority Trial. Lancet HIV. 2018;5(5):e211-e220.

22. Sluis-Cremer N, Temiz NA, Bahar I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res. 2004;2:323-332.

23. Sebastiao CS, Morais J, Brito M. Factors Influencing HIV Drug Resistance among Pregnant Women in Luanda, Angola: Findings from a Cross-Sectional Study. Trop Med Infect Dis. 2021;6(1):29.

24. ChagomereNA MB, Miller WC, Tang JH, Hoffman IF, Harrington BJ, DiPrete B, et al. Prevalence of antiretroviral therapy treatment failure among HIV-infected pregnant women at first antenatal care: PMTCT option b+ in Malawi. PLoS One. 2018;13(12):e0209052.

25. Wilhelmsen S, Mannson F, Lopatko Lindman J, Biai A, Esbjornsson J, Norrgren H, et al. Prevalence of HIV-1 pretreatment drug resistance among treatment naïve pregnant women in Bissau, Guinea Bissau. PloS one. 2018;13(10):e0206406.

Authors’ Contribution:

FK: Is responsible for the study design, data collection and write up.

MB: Contributed to the literature search and manuscript editing.

MYK: Is responsible for data analysis and literature search of the manuscript.

MF: Contributed to the write up and editing of the study.

All the authors are equally responsible for the integrity of the research work.